Serge brings significant experience in the life science industry across a range of roles and therapeutic areas, including hematology, oncology, immunology, and rare diseases.
Before joining DCVC Bio, Serge was CEO of Teon Therapeutics, an immuno-oncology biotech. Prior to that, as President of Janssen Oncology, a division of the Janssen Pharmaceutical Companies of Johnson & Johnson, he set the strategic direction for the organization, its key brands, and pipeline programs across hematology and solid tumors, as well as platforms including cell therapies and bi-specifics. He also held executive leadership roles at Johnson & Johnson’s Actelion, Baxalta, and Baxter International.
Serge holds a bachelor’s degree in physiology and biotechnology and a master’s degree in human genetics, both from McGill University, and an MBA from the University of Toronto.